Pulse Biosciences Announces Late-Breaking Clinical Study Results From nPulse Cardiac Surgical System First-In-Human Feasibility Study At 39th European Association For Cardio-Thoracic Surgery Annual Meeting

Successfully treated atrial fibrillation (AF) in initial 30 patients with the nPulse™ Cardiac Surgical System

Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced late-breaking clinical study results from the nPulse™ Cardiac Surgical System first-in-human feasibility study at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting in Copenhagen, Denmark.

The feasibility study is intended to assess the initial safety and efficacy of the nPulse Cardiac Surgical System for the treatment of Atrial Fibrillation (NCT06355063). To date, 44 patients have been treated by investigators in Europe, including Dr. Bart van Putte in cases performed at St. Antonius Hospital Nieuwegein, Netherlands, Dr. Bart Maesen performing cases at Maastricht UMC+, Maastricht, Netherlands, and Dr. Antoine Driessen performing cases at Amsterdam UMC, Amsterdam, Netherlands. In this initial cohort, 24 patients have had the ablation effectiveness and durability evaluated by electroanatomical mapping at approximately three months post the ablation procedure.